The present invention relates to a methyl-sulfonyl methane containing composition for preventing or alleviating obesity, fatty liver and diabetes. An MSM (methyl sulfonyl methane: dimethyl sulfone)-containing composition according to the present invention, which contains 75 to 85 wt. % of MSM, 0.5 to 2 wt. % of vitamin B6 hydrochloride, 0.01 to 1 wt. % of folic acid, 2 to 8 wt. % of galacto-oligosaccharide, 10 to 18 wt. % of rice-fermented magnesium, and 0.5 to 3 wt. % of vitamin C, not only can prevent and treat obesity by reducing the size of fat cells and inhibiting differentiation of mature fat cells, but also lowers triglyceride and the total cholesterol concentration in the liver, thus having a fatty liver preventing effect, and also reduces the concentration of insulin-like growth factor, thus also being effective for diabetes. Therefore, the MSM-containing composition is expected to be useful as a pharmaceutical composition and food composition for preventing and alleviating obesity, fatty liver and diabetes.

An object of the present invention is to provide a novel composition for use in suppressing fat accumulation, a novel composition for use in suppressing body weight gain, and a composition for use in promoting the production of a ketone body. According to the present invention, there is provided a composition for use in suppressing fat accumulation, suppressing body weight gain and/or promoting the production of a ketone body, comprising, as an active ingredient, a medium chain fatty acid glyceride comprising a saturated fatty acid having 8 carbon atoms as a constituent fatty acid. The ratio of the amount of the saturated fatty acid having 8 carbon atoms to the total amount of medium chain fatty acids of the medium chain fatty acid glyceride can be set to 0.6 or more. The medium chain fatty acid glyceride may further comprise, as a constituent fatty acid, a saturated fatty acid having 10 carbon atoms and/or a saturated fatty acid having 12 carbon atoms. The medium chain fatty acid glyceride is preferably a medium chain fatty acid triglyceride.

An object of the present invention is to provide a novel composition for use in suppressing fat accumulation, a novel composition for use in suppressing body weight gain, and a composition for use in promoting the production of a ketone body. According to the present invention, there is provided a composition for use in suppressing fat accumulation, suppressing body weight gain and/or promoting the production of a ketone body, comprising, as an active ingredient, a medium chain fatty acid glyceride comprising a saturated fatty acid having 8 carbon atoms as a constituent fatty acid. The ratio of the amount of the saturated fatty acid having 8 carbon atoms to the total amount of medium chain fatty acids of the medium chain fatty acid glyceride can be set to 0.6 or more. The medium chain fatty acid glyceride may further comprise, as a constituent fatty acid, a saturated fatty acid having 10 carbon atoms and/or a saturated fatty acid having 12 carbon atoms. The medium chain fatty acid glyceride is preferably a medium chain fatty acid triglyceride.

This invention relates to the use of a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis strain 420 (B420) for use in reducing food, energy and/or fat intake.

The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

The present invention relates to a pharmaceutical composition comprising pinocarveol for preventing or treating metabolic diseases, and functional food composition using the pharmaceutical composition for improving or alleviating metabolic diseases. Pinocarveol according to the present invention reduces weight, visceral fat, and cholesterol concentration, improves blood liver function index, reduces blood sugar, and additionally inhibits a metabolic inflammation reaction, and thus can be effectively used ultimately as a medical or functional food composition exhibiting prevention or treatment activities for metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, and syndromes of fatty liver and insulin-resistance.

The present invention relates to a pharmaceutical composition comprising pinocarveol for preventing or treating metabolic diseases, and functional food composition using the pharmaceutical composition for improving or alleviating metabolic diseases. Pinocarveol according to the present invention reduces weight, visceral fat, and cholesterol concentration, improves blood liver function index, reduces blood sugar, and additionally inhibits a metabolic inflammation reaction, and thus can be effectively used ultimately as a medical or functional food composition exhibiting prevention or treatment activities for metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, and syndromes of fatty liver and insulin-resistance.

The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.